MedTrace Logo

A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

NCT00963313 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2014-09-23

No results posted yet for this study

Summary

Based on published data and according to the approved product label for ankylosing spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days should be effective in psoriatic arthritic patients with axial involvement.

Conditions

Interventions

DRUG

Adalimumab (HUMIRA®)

Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.

Sponsors & Collaborators

  • Dr. FRANCISCO J. BLANCO-GARCIA

    lead OTHER

Principal Investigators

  • Francisco J. Blanco-Garcia, MD, PhD · Complejo Hospitalario Universitario A Coruna

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-06-30
Completion
2014-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963313 on ClinicalTrials.gov